Marchetti C, Rosati A, Scaletta G, et al. - In this case-control study, researchers focused on the role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) patients with BRCA1/2 mutation (BRCAmut) who were treated with platinum-based chemotherapy followed by olaparib maintenance. They identified 46 patients with first PSROC who were admitted to their Gynecologic Oncology Unit between 2014 and 2018. They matched cases [23 (50%) BRCAmut women receiving SCS followed by platinum-based chemotherapy and olaparib maintenance] to 23 (50%) BRCAmut women who only received medical therapy. In PSROC patients with BRCAmut candidate for olaparib maintenance following platinum-based chemotherapy, an increase in time to first subsequent therapy and post-recurrence survival was brought about by SCS. Individualizing indication to SCS was recommended in the era of personalized medicine.